How Becton Dickinson Makes its Money: Revenue Breakdown
A breakdown of Becton Dickinson (BDX) financials. See how Becton Dickinson makes money from BD Medical (Medication Delivery, Medication Management, Pharm Systems), BD Life Sciences (Biosciences, Diagnostics), BD Interventional (Surgery, Peripheral Intervention, Urology) using their 2024 annual report.
How Does Becton Dickinson Make its Money?
Becton, Dickinson and Company (BD) is a global medical technology company and one of the world’s largest manufacturers of medical supplies, devices, laboratory instruments, and diagnostic products. The company is best known for its syringes, needles, and blood collection systems — products used billions of times each year in hospitals, labs, and clinics worldwide. BD also provides medication management systems, infection prevention products, and diagnostic instruments. The company has been undergoing a planned separation to spin off its Biosciences segment into a standalone company to sharpen focus.
BD’s competitive moat comes from the sheer ubiquity and essential nature of its products. When a nurse draws blood, there’s a strong chance the Vacutainer tube and needle are made by BD. When a hospital administers IV medications, the syringe, infusion pump, and safety needle may all be BD products. These are consumable, disposable items used billions of times annually, creating recession-resistant recurring revenue. The company’s products are deeply embedded in hospital workflows, clinical protocols, and purchasing frameworks — creating switching costs that go far beyond the product itself.
Becton Dickinson (BDX) Business Model
Becton Dickinson Competitors
Becton Dickinson’s key competitors and comparable public companies in the medical devices sector include Abbott Laboratories, Stryker, Medtronic, and Boston Scientific. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Becton Dickinson stacks up by comparing their revenue breakdown, margins, and growth metrics.
Revenue Breakdown
| Segment | 2024 | 2023 | YoY Growth |
|---|---|---|---|
| BD Medical (Medication Delivery, Medication Management, Pharm Systems) | $10,100 | $9,700 | +4.1% |
| BD Life Sciences (Biosciences, Diagnostics) | $5,900 | $5,700 | +3.5% |
| BD Interventional (Surgery, Peripheral Intervention, Urology) | $4,300 | $4,000 | +7.5% |
| Total Revenue | $20,200 | $19,400 | +4.1% |
BD Medical (Medication Delivery, Medication Management, Pharm Systems) — 50% of Revenue
BD Medical is the largest segment and the historic core of the company. It encompasses three major sub-segments. Medication Delivery Solutions sells syringes, needles, IV catheters, and blood collection sets — the high-volume consumable products that make BD one of the most recognized names in healthcare. Medication Management Solutions provides infusion pumps (the BD Alaris system), pharmacy dispensing systems, and smart IV pump software that helps hospitals manage medication dosing and prevent errors. Pharmaceutical Systems sells prefillable syringes, self-injection devices, and drug delivery components to pharmaceutical companies that use them to package and deliver injectable drugs (a growing market as biologic drugs that require injection proliferate).
Revenue grew 4.1% in 2024, a steady pace reflecting the consumable-driven nature of the business. The Alaris infusion pump system had faced FDA scrutiny (a major voluntary recall and remediation effort), and the resolution of this issue has been a focus for management. Pharmaceutical Systems has been a strong performer, benefiting from the boom in GLP-1 drugs and other injectables that all require BD’s delivery devices.
BD Life Sciences (Biosciences, Diagnostics) — 29% of Revenue
BD Life Sciences provides flow cytometry instruments (cell sorting and analysis systems used in immunology, cancer research, and drug development), molecular diagnostics platforms, microbiology identification systems, and pre-analytical sample collection devices. The Biosciences sub-segment sells BD FACSymphony and other flow cytometry systems — the gold-standard instruments for characterizing cells in research and clinical labs. The Diagnostics sub-segment provides the BD MAX molecular diagnostic platform, BD Phoenix antimicrobial susceptibility testing, and BD BACTEC blood culture systems.
Revenue grew 3.5% in 2024, representing a normalization after the COVID-era surge in diagnostic testing demand that temporarily inflated this segment’s revenue. BD has announced plans to spin off the Biosciences sub-segment (flow cytometry and related research instruments) into a separate publicly traded company, allowing each business to pursue independent strategies and more focused capital allocation.
BD Interventional (Surgery, Peripheral Intervention, Urology) — 21% of Revenue
BD Interventional is the fastest-growing segment, selling surgical instruments (hernia repair mesh, soft tissue repair, biosurgery), peripheral vascular intervention products (venous stents, atherectomy devices, vascular access), and urology products (biopsy needles, drainage catheters). This segment has been built partly through acquisition and represents BD’s effort to move into higher-growth, higher-margin specialty medical devices. Revenue grew 7.5% in 2024, led by strong demand for venous stent systems and hernia repair products. This segment carries higher margins than the consumable-heavy Medical segment and is a strategic priority for growth.
Becton Dickinson (BDX) Income Statement
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $20,200 | $19,400 |
| Cost of Revenue | $10,300 | $10,000 |
| Gross Profit | $9,900 | $9,400 |
| Operating Expenses | $6,100 | $5,900 |
| Operating Income | $3,800 | $3,500 |
| Net Income | $2,200 | $1,600 |
All values in millions USD unless otherwise stated.
Financial data sourced from Becton Dickinson SEC Filings.
Becton Dickinson (BDX) Key Financial Metrics
- Gross Margin: 49.0%
- Operating Margin: 18.8%
- Revenue Growth: 4.1%
Is Becton Dickinson Profitable?
Yes, BD is profitable with improving margins. Net income jumped 38% to $2.2 billion in 2024, driven by resolution of one-time charges related to the Alaris pump remediation and steady operational improvements under the BD Excellence program. The 49.0% gross margin is solid for a company that manufactures physical medical products at massive scale — BD produces literally billions of individual devices per year. The 18.8% operating margin has room for expansion: management has targeted 25%+ adjusted operating margins through simplification, manufacturing efficiency, and mix shift toward higher-margin interventional products. The planned Biosciences spinoff should further clarify each entity’s profitability profile and allow the remaining BD to focus on its highest-return businesses.
Becton Dickinson (BDX): What to Watch
- Biosciences spinoff execution — The planned separation of the flow cytometry business into a standalone company is a major strategic event. Successful execution would unlock value and allow the remaining BD to focus on medication delivery and interventional products.
- Alaris pump resolution — The BD Alaris infusion pump system underwent a major voluntary recall and FDA remediation. Full resolution and return to market growth is critical for the Medication Management sub-segment.
- Injectable drug delivery tailwind — The boom in GLP-1 drugs (Ozempic, Mounjaro) and other biologics that require injection is driving demand for BD’s prefillable syringes and self-injection devices. This is a significant secular growth driver for Pharmaceutical Systems.
- BD Interventional growth — The Interventional segment growing at 7.5% represents BD’s shift toward higher-margin specialty devices. Continued above-company-average growth would improve the overall margin mix.
- Margin expansion — BD has historically operated at lower margins than medtech peers. The BD Excellence operational improvement program, combined with the Biosciences spinoff and Interventional growth, should drive meaningful margin expansion over the next several years.
Becton Dickinson (BDX) Financial Summary
Becton Dickinson is the invisible backbone of healthcare — its syringes, needles, blood collection systems, and infusion pumps are used billions of times annually in virtually every hospital, lab, and clinic worldwide. Revenue grew 4.1% to $20.2 billion in 2024, with the Interventional segment (21% of revenue) leading at 7.5% growth as BD shifts toward higher-margin specialty devices. Net income jumped 38% to $2.2 billion as Alaris-related remediation costs wound down and the BD Excellence program improved operational efficiency. The planned Biosciences spinoff will reshape the company, and the secular tailwind from the GLP-1 injectable drug boom is driving incremental demand for BD’s drug delivery devices. With a 49% gross margin and a clear path toward 25%+ adjusted operating margins, BD is positioned to accelerate earnings growth from its dominant but often overlooked market position.
Weekly Company Breakdowns — Visualized
See how top companies actually make money. Visual revenue breakdowns delivered free every week.